Dr. Mescheder joined Berlin Cures in June 2023 as Chief Medical Officer, with a background of over 30 years of clinical development and regulatory experience serving biotechnology, pharmaceutical and CRO companies.
Prior to joining Berlin Cures, Dr. Mescheder held various C-level positions in biotechnology companies.
At Berlin Cures he has a focus on the clinical development of the lead drug candidate BC007.
Dr. Mescheder has a track record of developing, implementing and driving clinical development programs, resulting in successful product registrations or label extensions in both Europe and the United States. Dr. Mescheder’s expertise includes the therapeutic areas of oncology, infectious diseases, immunology and inflammation. His responsibilities in these functions included among others clinical development, medical and scientific meetings with U.S. FDA, EMA and national European agencies, commercialization and registration activities, as well as organizing and chairing of international conferences, investigator meetings and participation in drug safety boards.
In addition to his position at Berlin Cures, Dr. Mescheder is member of leading international medical associations including ASCO, ESMO, ESCMID, DGPharMed/ IFAPP and he supports BioM/Martinsried as a mentor for biotech start-up companies.
Dr. Mescheder is a board-certified M.D. from the University of Kiel (Germany), with a medical license and full specialization in Pharmacology and Toxicology. He is author and co-author if peer-reviewed publications and presented at various international medical, scientific and business conferences.
